Cargando…
Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET
BACKGROUND: We investigated the relationship between metabolic activity and histological features of gliomas using fluorine-18α-methyltyrosine ((18)F-FAMT) positron emission tomography (PET) compared with fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET in 38 consecutive glioma patients. The tumor to...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451375/ https://www.ncbi.nlm.nih.gov/pubmed/28567708 http://dx.doi.org/10.1186/s13550-017-0298-8 |
_version_ | 1783240155507720192 |
---|---|
author | Horiguchi, Keishi Tosaka, Masahiko Higuchi, Tetsuya Arisaka, Yukiko Sugawara, Kenichi Hirato, Junko Yokoo, Hideaki Tsushima, Yoshito Yoshimoto, Yuhei |
author_facet | Horiguchi, Keishi Tosaka, Masahiko Higuchi, Tetsuya Arisaka, Yukiko Sugawara, Kenichi Hirato, Junko Yokoo, Hideaki Tsushima, Yoshito Yoshimoto, Yuhei |
author_sort | Horiguchi, Keishi |
collection | PubMed |
description | BACKGROUND: We investigated the relationship between metabolic activity and histological features of gliomas using fluorine-18α-methyltyrosine ((18)F-FAMT) positron emission tomography (PET) compared with fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET in 38 consecutive glioma patients. The tumor to normal brain ratios (T/N ratios) were calculated, and the relationships between T/N ratio and World Health Organization tumor grade or MIB-1 labeling index were evaluated. The diagnostic values of T/N ratios were assessed using receiver operating characteristic (ROC) curve analyses to differentiate between high-grade gliomas (HGGs) and low-grade gliomas (LGGs). RESULTS: Median T/N ratio of (18)F-FAMT PET was 2.85, 4.65, and 4.09 for grade II, III, and IV gliomas, respectively, with significant differences between HGGs and LGGs (p = 0.006). Both T/N ratio (p = 0.016) and maximum standardized uptake value (p = 0.033) of (18)F-FDG PET showed significant differences between HGGs and LGGs. ROC analysis yielded an optimal cut-off of 3.37 for the T/N ratio of (18)F-FAMT PET to differentiate between HGGs and LGGs (sensitivity 81%, specificity 67%, accuracy 76%, area under the ROC curve 0.776). Positive predictive value was 84%, and negative predictive value was 62%. T/N ratio of (18)F-FAMT PET was not correlated with MIB-1 labeling index in all gliomas, whereas T/N ratio of (18)F-FDG PET was positively correlated (r (s) = 0.400, p = 0.013). Significant positive correlation was observed between T/N ratios of (18)F-FDG and (18)F-FAMT (r (s) = 0.454, p = 0.004), but median T/N ratio of (18)F-FAMT PET was significantly higher than that of (18)F-FDG PET in all grades of glioma. CONCLUSIONS: The T/N ratio of (18)F-FAMT uptake has high positive predictive value for detection of HGGs. (18)F-FAMT PET had higher T/N ratio, with better tumor-normal brain contrast, compared to (18)F-FDG PET in both LGGs and HGGs. Therefore, (18)F-FAMT is a useful radiotracer for the preoperative visualization of gliomas. |
format | Online Article Text |
id | pubmed-5451375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-54513752017-06-16 Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET Horiguchi, Keishi Tosaka, Masahiko Higuchi, Tetsuya Arisaka, Yukiko Sugawara, Kenichi Hirato, Junko Yokoo, Hideaki Tsushima, Yoshito Yoshimoto, Yuhei EJNMMI Res Original Research BACKGROUND: We investigated the relationship between metabolic activity and histological features of gliomas using fluorine-18α-methyltyrosine ((18)F-FAMT) positron emission tomography (PET) compared with fluorine-18 fluorodeoxyglucose ((18)F-FDG) PET in 38 consecutive glioma patients. The tumor to normal brain ratios (T/N ratios) were calculated, and the relationships between T/N ratio and World Health Organization tumor grade or MIB-1 labeling index were evaluated. The diagnostic values of T/N ratios were assessed using receiver operating characteristic (ROC) curve analyses to differentiate between high-grade gliomas (HGGs) and low-grade gliomas (LGGs). RESULTS: Median T/N ratio of (18)F-FAMT PET was 2.85, 4.65, and 4.09 for grade II, III, and IV gliomas, respectively, with significant differences between HGGs and LGGs (p = 0.006). Both T/N ratio (p = 0.016) and maximum standardized uptake value (p = 0.033) of (18)F-FDG PET showed significant differences between HGGs and LGGs. ROC analysis yielded an optimal cut-off of 3.37 for the T/N ratio of (18)F-FAMT PET to differentiate between HGGs and LGGs (sensitivity 81%, specificity 67%, accuracy 76%, area under the ROC curve 0.776). Positive predictive value was 84%, and negative predictive value was 62%. T/N ratio of (18)F-FAMT PET was not correlated with MIB-1 labeling index in all gliomas, whereas T/N ratio of (18)F-FDG PET was positively correlated (r (s) = 0.400, p = 0.013). Significant positive correlation was observed between T/N ratios of (18)F-FDG and (18)F-FAMT (r (s) = 0.454, p = 0.004), but median T/N ratio of (18)F-FAMT PET was significantly higher than that of (18)F-FDG PET in all grades of glioma. CONCLUSIONS: The T/N ratio of (18)F-FAMT uptake has high positive predictive value for detection of HGGs. (18)F-FAMT PET had higher T/N ratio, with better tumor-normal brain contrast, compared to (18)F-FDG PET in both LGGs and HGGs. Therefore, (18)F-FAMT is a useful radiotracer for the preoperative visualization of gliomas. Springer Berlin Heidelberg 2017-05-31 /pmc/articles/PMC5451375/ /pubmed/28567708 http://dx.doi.org/10.1186/s13550-017-0298-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Research Horiguchi, Keishi Tosaka, Masahiko Higuchi, Tetsuya Arisaka, Yukiko Sugawara, Kenichi Hirato, Junko Yokoo, Hideaki Tsushima, Yoshito Yoshimoto, Yuhei Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET |
title | Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET |
title_full | Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET |
title_fullStr | Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET |
title_full_unstemmed | Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET |
title_short | Clinical value of fluorine-18α-methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET |
title_sort | clinical value of fluorine-18α-methyltyrosine pet in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose pet |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451375/ https://www.ncbi.nlm.nih.gov/pubmed/28567708 http://dx.doi.org/10.1186/s13550-017-0298-8 |
work_keys_str_mv | AT horiguchikeishi clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet AT tosakamasahiko clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet AT higuchitetsuya clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet AT arisakayukiko clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet AT sugawarakenichi clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet AT hiratojunko clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet AT yokoohideaki clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet AT tsushimayoshito clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet AT yoshimotoyuhei clinicalvalueoffluorine18amethyltyrosinepetinpatientswithgliomascomparisonwithfluorine18fluorodeoxyglucosepet |